Last updated on April 2020

An Open-label Study of ALPN-202 in Subjects With Advanced Malignancies

Brief description of study

This is a cohort-based, open-label dose escalation and expansion study in adults with advanced solid tumors or lymphoma, refractory or resistant to standard therapy, or without available standard or curative therapy.

Clinical Study Identifier: NCT04186637

Find a site near you

Start Over